Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Cravacin is indicated for:
Pharmacology
Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2), which belongs to the Janus kinase (JAK) family. It binds to the regulatory domain of TYK2 and stabilizes an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. The result is allosteric inhibition of receptor-mediated activation of TYK2, and of its downstream activation of Signal Transducers and Activators of Transcription (STATs), as shown in cell-based assays.
JAK kinases, TYK2 included, work as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to mediate multiple cytokine pathways, and it also pairs with JAK2 to transmit signals, again as shown in cell-based assays. How inhibiting the TYK2 enzyme leads to a therapeutic effect in adults with moderate-to-severe plaque psoriasis is not currently known.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended Evaluations and Immunizations Prior to Treatment Initiation
Check patients for active and latent tuberculosis (TB) infection before starting Deucravacitinib. If the result is positive, begin TB treatment first, then start Deucravacitinib.
Recommended Dosage
The recommended dosage of Deucravacitinib is 6 mg taken orally once daily, with or without food. Don't crush, cut or chew the tablets.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use
No overall differences in effectiveness have been observed between patients aged 65 years and older and younger adult patients.
Recommended Dosage in Patients with Hepatic Impairment
Deucravacitinib is not recommended in patients with severe hepatic impairment (Child-Pugh C). Patients with mild to moderate hepatic impairment need no dosage adjustment.
Renal Impairment
No dose adjustment is recommended in patients with mild, moderate or severe renal impairment, or in patients with end stage renal disease (ESRD) on dialysis.
Side Effects
Deucravacitinib (sold as Deucrava) most often causes common cold, sore throat and sinus infection (upper respiratory infections). Other common side effects are cold sores (herpes simplex), sores on the inner lips, gums, tongue or roof of the mouth (canker sores), inflamed hair pores (folliculitis) and acne. It may also cause serious allergic reactions. These include feeling faint, swelling in the face, eyelids, lips, mouth, tongue or throat, trouble breathing, throat tightness or chest tightness, skin rash, hives and similar signs.
Cautions & Contraindications
Warnings & Precautions
Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported with Deucravacitinib. If a clinically significant hypersensitivity reaction occurs, stop the medicine. Infections: Deucrava may increase the risk of infection, so avoid it in patients with an active or serious infection. If a serious infection develops, stop Deucrava until the infection resolves. Tuberculosis: Check for TB before starting treatment with Deucrava. Malignancy: Malignancies, including lymphomas, were observed in clinical trials with Deucrava. Laboratory abnormalities: Serum triglycerides should be checked periodically. Liver enzymes should be checked at baseline, and after that in patients with known or suspected liver disease. Immunizations: Avoid use with live vaccines. Potential risks related to JAK inhibition: It is not known whether TYK2 inhibition may be linked with the adverse reactions seen, or possible, with JAK inhibition. In rheumatoid arthritis (RA) patients, higher rates of all-cause mortality were seen with a JAK inhibitor than with TNF blockers. This included sudden cardiovascular death. Major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism and malignancies (excluding non-melanoma skin cancer) were also higher. Deucrava is not approved for use in RA. Rhabdomyolysis and elevated CPK.
Contraindications
Don't give Deucravacitinib to anyone who has had a hypersensitivity reaction to Deucravacitinib itself, or to any of the excipients in the preparation.
Pregnancy & Breastfeeding
Case reports on Deucravacitinib use in pregnancy don't give enough information to judge whether the medicine carries a risk of major birth defects, miscarriage, or other bad outcomes for the mother or the baby. In animal reproductive studies, no effect on embryo-fetal development was seen.
Nothing is known about whether Deucravacitinib passes into human milk, what it does to a breastfed infant, or whether it changes milk production. So the benefits of breastfeeding for the baby's development and health should be weighed together with the mother's clinical need for Deucravacitinib, and with any possible adverse effects of the medicine on the breastfed infant.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Store Deucravacitinib below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Drug Interactions
Common questions about Cravacin 6 mg
What is Cravacin 6 mg Tablet?
Cravacin 6 mg Tablet is a medicine that contains Deucravacitinib. It is made by Everest Pharmaceuticals Ltd. It belongs to the Topical Antifungal preparations group of medicines.
What is Cravacin used for?
Cravacin is used for: Psoriasis.
What are the side effects of Cravacin?
Deucravacitinib (sold as Deucrava) most often causes common cold, sore throat and sinus infection (upper respiratory infections). Other common side effects are cold sores (herpes simplex), sores on the inner lips, gums, tongue or roof of the mouth (canker sores), inflamed hair pores (folliculitis) and acne.
Can I take Cravacin during pregnancy or while breastfeeding?
Case reports on Deucravacitinib use in pregnancy don't give enough information to judge whether the medicine carries a risk of major birth defects, miscarriage, or other bad outcomes for the mother or the baby. In animal reproductive studies, no effect on embryo-fetal development was seen. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Cravacin?
Store Deucravacitinib below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Is there a cheaper medicine with the same ingredient?
Cravacin is already among the lowest-priced brands of Deucravacitinib at this strength.
Do I need a prescription for Cravacin?
Cravacin is a prescription (Rx) medicine. Take it as your doctor advises.